Bottom‑line vs. the Street
Aardvark Therapeutics posted Q2 revenue of roughly **$12.5 million, which came in below the consensus estimate of about **$14.0 million from the broker community. The company’s net loss widened to approximately **$42 million, versus the $36–$37 million loss that analysts had been forecasting. In other words, top‑line sales missed expectations by roughly 10 %, while the bottom line loss was 13‑15 % deeper than the consensus.
Trading take‑aways
The shortfall on both revenue and earnings‑per‑share (loss) is likely to pressure the stock in the near term, especially given the modest “30‑point” sentiment rating, which signals a relatively neutral tone but with a slight downside bias. Sellers may look to test support around the recent low‑15 % range (≈$8.20‑$8.40), while long‑biased traders could target a bounce off the 20‑day moving average (~$9.10) on the assumption that the market will eventually re‑price the stock on pipeline‑related catalysts rather than a single quarter’s earnings miss. Keep an eye on upcoming catalyst dates (Phase II read‑outs, partnership announcements) — a positive data point could offset the earnings disappointment and provide a short‑term buying opportunity.